A prediction of 2025 by Doug Mirsky, Ph.D., vice president of healthcare delivery at Digital Medicine Society.
There are 350,000 digital health software products (DHSPs) available today, with that number only growing — and more than 6,000 hospitals in the U.S. trying to figure out how to navigate through this massive market problem.
Mirsky
Although most larger hospitals and systems have digital health teams and the equivalent of a chief digital officer to resource how to approach this market to efficiently adopt those products that best fit their needs, most smaller hospitals will come to rely upon third-party evaluations to keep pace. For those smaller hospitals, quickly getting to a place of quality and trust with DHSPs will be a lifeline to supporting care in their communities and continuing to deliver to those patients in need while maintaining financial stability and supporting staffing challenges.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
February 12th 2025Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.
Read More